Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with monoclonal immunoglobulin deposition disease (a condition where abnormal proteins build up in the body's organs) and have not yet received treatment targeting the abnormal plasma cells causing it.
- People who are reasonably active and able to care for themselves, either fully or with some limitations (confirm with trial site).
- People whose blood test results show that their white blood cells, red blood cells, and platelets are at or above certain minimum levels (confirm with trial site for exact values).
- People whose liver function blood tests are within an acceptable range, specifically bilirubin, AST, and ALT levels (confirm with trial site for exact values).
- People who have had the trial explained to them, understood it, and signed a consent form agreeing to take part.
Who may not be able to join:
- People who have already received treatment for this condition, except for a small amount of steroid medication (dexamethasone or a similar steroid at a low equivalent dose).
- People who also meet the criteria for active multiple myeloma or a related blood condition called active lymphoplasmacytic lymphoma.
- People who have another cancer that is at an advanced stage and has spread to other parts of the body.
- People who have a serious or ongoing infection that cannot be controlled with treatment.
- People who have a serious autoimmune disease or a condition that severely weakens the immune system.
- People who have active hepatitis B or hepatitis C, as shown by positive virus levels on blood tests.
- People who have HIV or syphilis.
- People where the research team believes participation would increase health risks or affect the reliability of the study results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jin Lu, Peking University People's Hospital
Phone: 86-13311491805
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of Hematologic Complete Response at the completion of 6 cycles
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.